newsfilter
← Latest News
GlobeNewswire·

Oncternal Therapeutics Announces Strategic Reprioritization and Capital Preservation, Extends Cash Runway into 2025

Zilovertamab Phase 3 Study ZILO-301 and Phase 1/2 Study CIRM-0001 to be closed based on dynamically changing therapeutic landscapeCash runway extended to 2025, enabling initial clinical data readouts for both ONCT-808,